ClinicalTrials.Veeva

Menu

Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation (AF) (Code-AF Trial)

Yonsei University logo

Yonsei University

Status

Enrolling

Conditions

Atrial Fibrillation

Study type

Observational

Funder types

Other

Identifiers

NCT02786095
4-2016-0105

Details and patient eligibility

About

This study is prospective Cohort study which was performed in multicenter (General Hospital) in Korea. Inclusion criteria is all patients with atrial fibrillation who visit hospital. The purpose is to analyze complication, composite outcome (all cause mortality, hospitalization, the incidence of stroke, heart failure and cardiovascular event (MACE)) according to the 1) the use of anti-arrhythmic drugs (AADs), 2) use of medication for rate control (beta blocker, calcium channel blocker and digoxin) and 3) use of anticoagulation agents (warfarin, coumadin, an NOAC)

Enrollment

20,000 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients with atrial fibrillation
  • patients with age more than 19
  • patients who agree with study inclusion

Exclusion criteria

  • patients who do not agree with study inclusion
  • patients with age less than 19
  • Pregnancy, Breastfeeding

Trial design

20,000 participants in 1 patient group

Code-AF registry

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems